Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16569783 | 0.97 | CA1 (0.33) | ACHE | |
| SCHEMBL301584 | 0.97 | CA1 (0.33) | ACHE | |
| SCHEMBL8788188 | 0.87 | — | — | |
| SCHEMBL14620409 | 0.82 | — | — | |
| SCHEMBL11122661 | 0.81 | ACHE (0.30) | ACHE | |
| SCHEMBL1704223 | 0.81 | ACHE (0.30) | ACHE | |
| SCHEMBL3671534 | 0.80 | — | — | |
| SCHEMBL3668696 | 0.80 | — | — | |
| SCHEMBL3668698 | 0.80 | — | — | |
| SCHEMBL1049096 | 0.79 | CA1 (0.33) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119569-A1 | Curable and Solvent Soluble Formulations and Methods of Making and Using Therof | POLY6 TECHNOLOGIES, INC. | 2022-04-21 | — | — | US | claimed |
| US-20200062877-A1 | Curable and Solvent Soluble Formulations and Methods of Making and Using Therof | POLY6 TECHNOLOGIES, INC. | 2020-02-27 | — | — | US | claimed |
| WO-2018156766-A2 | CURABLE AND SOLVENT SOLUBLE FORMULATIONS AND METHODS OF MAKING AND USING THEREOF | POLY6 TECHNOLOGIES, INC. (US) | 2018-08-30 | — | — | WO | claimed |
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-16 | — | — | US | disclosed |
| EP-4192838-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | Dana-Farber Cancer Institute, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20220119569-A1 | Curable and Solvent Soluble Formulations and Methods of Making and Using Therof | POLY6 TECHNOLOGIES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-20210276077-A1 | ARTICLES AND METHODS OF MANUFACTURE | HPS INVESTMENT PARTNERS, LLC, AS COLLATERAL AGENT | 2021-09-09 | — | — | US | disclosed |
| EP-3823775-A1 | ARTICLES AND METHODS OF MANUFACTURE | Poly6 Technologies, Inc. (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20200062877-A1 | Curable and Solvent Soluble Formulations and Methods of Making and Using Therof | POLY6 TECHNOLOGIES, INC. | 2020-02-27 | — | — | US | disclosed |
| WO-2018156766-A2 | CURABLE AND SOLVENT SOLUBLE FORMULATIONS AND METHODS OF MAKING AND USING THEREOF | POLY6 TECHNOLOGIES, INC. (US) | 2018-08-30 | — | — | WO | disclosed |
| US-6271408-B1 | Process for making metabolites of lycopene | ROCHE VITAMINS INC. | 2001-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | USP28, USP30, USP8 | ACHE 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.